EGFR and neoplasm: Like SCPC, LUAD undergoes NET through LUAD – small-cell lung cancer (SCLC) transition, which enables the tumor to escape from EGFR-TKI treatment and gain a higher level of malignancy.48,54,66 Although NET is also identified in non-EGFR-mutant NSCLC, EGFR mutant LUADs are more likely to switch lineage.67 Oser et al.68 reported that 5–15% of EGFR mutant LUAD patients with TKI resistance showed small cell histology in relapsed tumors, and became sensitive to SCLC chemotherapy.48 The mechanism of LUAD NET at the molecular level is similar to that of PC NET.